Immunomedics, Inc. (NASDAQ:IMMU) shares traded down 6.2% during trading on Tuesday . The company traded as low as $11.44 and last traded at $11.64. 2,489,742 shares changed hands during trading, a decline of 2% from the average session volume of 2,535,080 shares. The stock had previously closed at $12.41.

A number of research analysts have recently commented on the stock. Jefferies Group LLC set a $9.00 price objective on shares of Immunomedics and gave the company a “buy” rating in a research report on Saturday, June 10th. Zacks Investment Research lowered shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 23rd. ValuEngine raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Cowen and Company assumed coverage on shares of Immunomedics in a research report on Friday, May 26th. They set an “outperform” rating for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $12.00.

The company’s 50-day moving average price is $9.59 and its 200 day moving average price is $7.65. The company’s market capitalization is $1.30 billion.

Immunomedics (NASDAQ:IMMU) last announced its earnings results on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.13). The company had revenue of $0.64 million for the quarter, compared to analyst estimates of $0.75 million. The business’s revenue for the quarter was down 31.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.17) earnings per share. On average, equities research analysts forecast that Immunomedics, Inc. will post ($0.55) EPS for the current fiscal year.

In other Immunomedics news, insider David M. Goldenberg sold 20,000 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $12.64, for a total value of $252,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Cynthia L. Goldenberg sold 40,000 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $9.24, for a total transaction of $369,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,051,200 in the last ninety days. 6.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of IMMU. Teachers Advisors LLC boosted its holdings in Immunomedics by 8.9% in the 4th quarter. Teachers Advisors LLC now owns 185,661 shares of the biopharmaceutical company’s stock valued at $681,000 after purchasing an additional 15,147 shares during the period. Russell Investments Group Ltd. bought a new stake in Immunomedics in the 1st quarter valued at about $383,000. Bank of New York Mellon Corp boosted its holdings in Immunomedics by 5.3% in the 1st quarter. Bank of New York Mellon Corp now owns 464,215 shares of the biopharmaceutical company’s stock valued at $3,003,000 after purchasing an additional 23,518 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in Immunomedics by 361.2% in the 1st quarter. UBS Asset Management Americas Inc. now owns 67,301 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 52,709 shares during the period. Finally, TD Asset Management Inc. bought a new stake in Immunomedics in the 1st quarter valued at about $855,000. 77.99% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/12/immunomedics-inc-immu-stock-price-down-6-2.html.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Stock Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related stocks with our FREE daily email newsletter.